Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127973471 | 12797347 | 1 | I | 20150512 | 20160930 | 20160930 | EXP | DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2015RR-116733 | RANBAXY | KUNZMANN V , HERRMANN K , BLUEMEL C , KAPP M , HARTLAPP I , STEGER U. INTENSIFIED NEOADJUVANT CHEMOTHERAPY WITH NAB-PACLITAXEL PLUS GEMCITABINE FOLLOWED BY FOLFIRINOX IN A PATIENT WITH LOCALLY ADVANCED UNRESECTABLE PANCREATIC CANCER. CASE REPORTS IN ONCOLOGY. 2014;7 (3):648-55 | 46.00 | YR | F | Y | 0.00000 | 20160930 | OT | DE | DE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127973471 | 12797347 | 1 | SS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | Unknown | 1000 MG/M2 ON DAYS 1, 8 AND 15, REPEATED ON 29 | U | 0 | |||||||||
| 127973471 | 12797347 | 2 | SS | OXALIPLATIN. | OXALIPLATIN | 1 | Unknown | 85 MG/M2 ON DAY 1 | U | 0 | |||||||||
| 127973471 | 12797347 | 3 | SS | Calcium folinat | LEUCOVORIN CALCIUM | 1 | Unknown | 400 MG/M2 ON DAY 1 | U | U | 0 | ||||||||
| 127973471 | 12797347 | 4 | PS | Irinotecan | IRINOTECAN | 1 | Unknown | 180 MG/M2 ON DAY 1 | U | U | 78805 | ||||||||
| 127973471 | 12797347 | 5 | SS | Nab-paclitaxel | PACLITAXEL | 1 | Unknown | 125 MG/M2 DAYS 1, 8, 15, REPEATED ON 29 | U | 0 | |||||||||
| 127973471 | 12797347 | 6 | SS | FLUOROURACIL. | FLUOROURACIL | 1 | Unknown | 2400 MG/M2, CONTINUOUS INFUSION OVER 46 HR | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127973471 | 12797347 | 1 | Pancreatic carcinoma |
| 127973471 | 12797347 | 2 | Pancreatic carcinoma |
| 127973471 | 12797347 | 3 | Pancreatic carcinoma |
| 127973471 | 12797347 | 4 | Pancreatic carcinoma |
| 127973471 | 12797347 | 5 | Pancreatic carcinoma |
| 127973471 | 12797347 | 6 | Pancreatic carcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127973471 | 12797347 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127973471 | 12797347 | Diarrhoea | |
| 127973471 | 12797347 | Fatigue | |
| 127973471 | 12797347 | Neuropathy peripheral | |
| 127973471 | 12797347 | Neutropenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |